诺和诺德（NVO）股价在夜盘交易中大涨5.07%，引发市场关注。该公司今日发布的2025年第一季度财报显示，业绩表现优于市场预期，但同时下调了全年销售额和盈利预期。
财报显示，诺和诺德第一季度销售额达780.9亿丹麦克朗，同比增长19%；净利润290.3亿丹麦克朗，同比增长14%，超过市场预期的279.1亿丹麦克朗。然而，公司旗下明星减肥药Wegovy的销售额为173.6亿丹麦克朗，低于市场预期的189.8亿丹麦克朗。
尽管第一季度业绩强劲，诺和诺德仍下调了2025年全年展望。公司现预计全年销售额增长率（按固定汇率计算）为13-21%，低于此前预期的16-24%；营业利润增长率预计为16-24%，也低于此前预期。诺和诺德表示，下调预期主要是由于美国GLP-1仿制药的快速扩张，导致品牌GLP-1药物的渗透率低于预期。尽管如此，投资者似乎对公司的整体表现持乐观态度，推动股价上涨。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.